New library preparation solutions offer never before achieved scale for the Revio™ sequencing system.

Providing precise, consistent results, Applied Biosystems™ thermal cyclers are designed for every challenge, application, and budget.

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk.

Through an exclusive new partnership with ProtonDx, (London, UK), Alpha Laboratories (Eastleigh, UK) proudly announces the launch of SmartLid™, a magnetic key and lid system that streamlines the nucleic acid extraction process.

Ultra Optically Clear assay plates from Azenta Life Sciences provide high optical transmission in the UV waveband, making them ideal for labs tasked with DNA purity measurements performed at 260 / 280nm.

License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced its second Japanese Patent.

Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site. The site will feature a new state-of-the-art genomics lab scheduled to open in early 2024.

The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions such as life-saving vaccines.